Ads
related to: calvert formula for carboplatin
Search results
Results From The WOW.Com Content Network
Calvert formula: () = (+) The typical area under the curve (AUC) for carboplatin ranges from 3-7 (mg/ml)*min. [ 14 ] GFR (Glomerular Filtration Rate) is a measure or estimate of kidney function. This is either measured, by measuring clearance of a radioisotope or estimated using serum and (sometimes) urine creatine measurements.
Notable examples include the anticancer drugs cisplatin, [PtCl 2 (NH 3) 2], and carboplatin. Many homogeneous catalysts are square planar in their resting state, such as Wilkinson's catalyst and Crabtree's catalyst. Other examples include Vaska's complex and Zeise's salt. Certain ligands (such as porphyrins) stabilize this geometry.
In this form of chemotherapy, commonly used drugs include cisplatin, oxaliplatin, and carboplatin, but several have been proposed or are under development. [1] Addition of platinum-based chemotherapy drugs to chemoradiation in women with early cervical cancer seems to improve survival and reduce risk of recurrence.
the main page says "Formula C6H14N2O4Pt" and "Mol. mass 371.249 g/mol", however in the picture shown I see only 12 hydrogen atom white balls, and if you add up the weight of all atoms, 14 H's gives you 2 higher than the 371 weight.
Pemetrexed is also recommended in combination with carboplatin and pembrolizumab for the first-line treatment of advanced non-small cell lung cancer. [12] [13] However, the relative efficacy or toxicity of pemetrexed-cisplatin versus pemetrexed-carboplatin has not been established beyond what is generally thought about cisplatin or carboplatin doublet drug therapy.
Carboplatin, an example of a metallopharmaceutical. A metallopharmaceutical is a drug that contains a metal as an active ingredient. [1] [2] Most commonly metallopharmaceuticals are used as anticancer or antimicrobial agents. The efficiency of metallopharmaceuticals is crucially dependent on the respective trace metal binding forms. [3]
Clinical trial number NCT01154140 for "A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung (PROFILE 1014)" at ClinicalTrials.gov
Combination trials have evaluated veliparib in combination with doxorubicin, temozolomide, topotecan, carboplatin, paclitaxel, pemetrexed, cyclophosphamide, gemcitabine, and others. [ 4 ] By June 2014 it was in three phase III trials, for advanced ovarian cancer, triple-negative breast cancer and in non-small cell lung cancer (NSCLC). [ 8 ]